For UK MedTech companies
Your reps carry the entire sale while clinicians stay silent
NHS procurement committees weight peer endorsement heavily. Without a structured clinical champion network, every deal depends on your sales team alone, and that ceiling is low.
Two minutes. Solva follows up with specific clinical engagement options.
- Sales representatives spending excessive time on individual account development without broader clinical endorsement
- Limited uptake of innovative MedTech products despite clear clinical benefits
- Difficulty in securing speaking slots or abstract acceptances at key clinical conferences
- Slow market penetration and reliance on a few key opinion leaders rather than a broader network of advocates.
- Inefficient sales force deployment and increased cost per sale
- Slower market penetration and adoption of new technologies
- Extended sales cycles leading to delayed revenue recognition and reduced annual sales
- Higher customer acquisition costs due to reliance on direct sales efforts
- Perception of the company as a 'sales-driven' rather than 'clinically-led' organisation
- Limited credibility within specialist clinical communities
No verified UK data available
Source: No verified UK data available
Frequently asked questions
Why does this problem persist?
MedTech adoption in NHS and private hospitals is heavily peer-driven. Procurement committees give significant weight to clinical champion endorsement. Without a structured KOL and clinical champion programme, even a superior product struggles to gain traction beyond the accounts where reps have personal relationships.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.